Gattefossé has opened a new manufacturing facility in Lufkin, Texas dedicated to pharmaceutical excipient production. The site marks the company’s first excipient manufacturing footprint in the United States, reflecting growing demand for domestic supply chain resilience in pharmaceutical ingredients.
The Lufkin facility will produce a range of lipid-based excipients used in oral solid dosage forms, injectables, and topical formulations. By expanding operations in the U.S., the company aims to support pharmaceutical manufacturers with reliable local supply, reduce dependence on overseas imports, and respond to an increased focus on domestic manufacturing capacity.
Gattefossé stated that the facility is designed in compliance with current Good Manufacturing Practice (cGMP) standards and incorporates modern technologies to ensure quality, safety, and scalability. The site is also expected to serve as a technical hub for formulation support, providing pharmaceutical partners with expertise in drug delivery and excipient functionality.
Industry experts note that the investment aligns with broader trends toward strengthening supply chain security and enhancing excipient innovation to meet the needs of complex drug formulations. The Texas expansion complements Gattefossé’s global network and positions the company to play a more prominent role in the U.S. pharmaceutical market.